Regulus Therapeutics Inc. engages in the development of drugs designed to inhibit dysregulated microRNA targets for the benefit of patients with genetically based orphan diseases. The company develops farabursen, an anti-miR oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. It is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was formerly known as Regulus Therapeutics LLC and changed its name to Regulus Therapeutics Inc. in January 2009. The company was incorporated in 2007 and is based in San Diego, California. As of June 25, 2025, Regulus Therapeutics Inc. operates as a subsidiary of Novartis AG. Show more

Location: 4224 Campus Point Court, San Diego, CA, 92121, United States | Website: https://www.regulusrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

565M

52 Wk Range

$0.83 - $8.35

Previous Close

$8.16

Open

$8.16

Volume

N/A

Day Range

$8.16 - $8.16

Enterprise Value

501M

Cash

65.37M

Avg Qtr Burn

-10.89M

Insider Ownership

2.71%

Institutional Own.

82.87%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date